Anticoagulation Highlights From the American Heart Association Meeting 2017

Program Goals

Differences Between Clinical Trial Data and Real-World Evidence

Advantages and Disadvantages of Using Real-World Data

Impact of NOAC Adherence on Clinical Outcomes Among Patients With AF

Real-World Evidence NOAC Use in Elderly Populations

Outcomes of Rivaroxaban vs Warfarin in NVAF Patients ≥ 80 Years of Age

PIONEER AF-PCI

PIONEER AF-PCI: Clinically Significant Bleeding[a] and Hospitalization[b]

RE-DUAL PCI

RE-DUAL PCI ISTH Major or CRNM Bleeding

Danish Registry: Patients With NVAF and MI Treated with OAC and Antiplatelet Therapy

NOAC Use in Patients With Cancer

NOAC Use in Cancer VTE-Related HRU Comparison Between Cohorts

Hokusai VTE-Cancer, SELECT-D

Summary Data on NOACs

Summary (cont)

Abbreviations

Abbreviations (cont)